The evidence on peptides — delivered weekly. Subscribe free →

Cholecystokinin

low risk

Also: CCK · CCK-8 · Satiety hormone

Strong Evidence Research Only

Reference entry for cholecystokinin (CCK), the primary GI satiety hormone released from duodenal I-cells in response to fat and protein. Signals fullness via vagal afferents and hypothalamic CCK receptors. CCK-1 receptor agonism is a drug target for obesity.

Molecular Weight
1143.3 Da (CCK-8)
Formula
C49H62N10O13S
Common Dosing
Not used therapeutically in native form
Category
research
Last Reviewed
2025-01-15

Reported Benefits

Satiety signaling

Strong Evidence 340 studies

Well-characterized GI satiety hormone. CCK-1 receptor agonism is active drug target for obesity pharmacology.

Mechanism of Action

Released from duodenal I-cells post-meal; acts on CCK-1 (CCK-A) receptors on vagal afferents; stimulates pancreatic enzyme and bile secretion; inhibits gastric emptying; signals satiety to hypothalamus.

Relevance to Obesity Pharmacology

CCK-1 receptor agonists are an active target class for obesity drug development. Understanding native CCK physiology provides context for interpreting early-stage compounds targeting this pathway.

Regulatory Status

Research Only

Safety Profile

Side Effects

  • •Not applicable

Contraindications

  • •N/A

Primary Uses

Satiety signalingDigestive enzyme releaseGI motilityEducational reference

Related Peptides

semaglutideghrelincagrilintide

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe Cholecystokinin?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.